 SAN DIEGO, Sept. 08, 2021 GLOBE NEWSWIRE -- Metacrine, Inc. NASDAQ:MTCR, a clinical-stage biopharmaceutical company pioneering differentiated therapies for patients with liver and gastrointestinal diseases, today announced it will host a virtual RD Day for analysts and investors on Wednesday, September 15, 2021 at 12:00 p.m. ET. The event will showcase Metacrines programs in non-alcoholic steatohepatitis NASH and inflammatory bowel disease IBD, as well as the introduction of a new discovery program. 